Antibodies

11 Oct 2019 Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
10 Oct 2019 Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
10 Oct 2019 Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
10 Oct 2019 Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
09 Oct 2019 Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
08 Oct 2019 ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
08 Oct 2019 Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
07 Oct 2019 Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
04 Oct 2019 New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
04 Oct 2019 I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
04 Oct 2019 FASENRA (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
03 Oct 2019 Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
02 Oct 2019 Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
02 Oct 2019 Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
01 Oct 2019 OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
01 Oct 2019 Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
01 Oct 2019 Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)
01 Oct 2019 AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
01 Oct 2019 Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
30 Sep 2019 Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
30 Sep 2019 Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
30 Sep 2019 Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)
30 Sep 2019 Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top